8 results about "Cellular dna" patented technology

Provided herein are compositions comprising a particle comprising a library encoded bead (e.g., DEL bead) coated in a polymeric matrix forming a core-shell particle, wherein the core-shell particle is further inside a 3D tissue culture. Also provided herein are methods of making such particles, and methods of using such particles for drug discovery such as identification of bioactive compounds via high-throughput cellular activity-based phenotypic screens of DNA-encoded chemical library beads.

Cells with stably integrated exogenous nucleic acid sequences (e.g., transgenes) into their genome are disclosed, said exogenous nucleic acid sequences being located within or near an integration site containing at least a portion of an endogenous retrovirus (ERV) or LTR-retrotransposon (LTR-RT), or replacing sequences containing ERVs or LTR-RTs that are part of or formerly part of the cell genome, as well as methods for producing and using such cells. Advantageously, high levels and / or stable production of transgene expression products can be achieved. Transgene integration and expression can be promoted by modulating cellular DNA repair pathways, for example, by transiently expressing genes encoding proteins that form part of DNA repair pathways during transgene integration.

Disclosed are an extract of Caterpillar Fungus, and a method for preparing the same and use thereof. The extract of caterpillar fungus is obtained by extracting caterpillar fungus with a polyol aqueous solution and EDTA-4Na, and filtering and removing impurities. The extract is free of DNA, and can repair cellular DNA damage caused by ultraviolet light, inhibit the production of cyclobutane pyrimidine dimers, thereby reducing or treating skin photoaging. Furthermore, the use of stabilizers and preservatives can be reduced or avoided in the cosmetics prepared based on the extract, which meets the general requirements of consumers for the safety of cosmetics and improves the compliance.

The application provides a white light-based cell DNA quantitative analysis method, comprising the following steps: S1, acquiring an RGB color image of cells by using a color camera and a white light source; S2, performing gray scale processing on the color image by using a dark average elimination method; S3, generating a mask of a cell protoplast region by using a threshold segmentation method; S4, extracting all the cell nucleus candidate contours in the gray scale image by using a gray scale binary method and a gradient amplitude method respectively, and performing merging and de-duplication processing on the cell nucleus candidate contours extracted by the two methods to obtain a cell nucleus contour set; and S5, performing quantitative analysis on cell DNA in the cell nucleus contour region by using a light absorption entropy integral value algorithm. The application adopts a one-time imaging mode of a white light source combined with a color camera, replaces the complex process of multiple imaging by relying on multiple specific wavelength light sources in the traditional method, significantly reduces the equipment manufacturing cost and maintenance difficulty, and effectively improves the image acquisition efficiency and the stability of the system.

The present disclosure provides methods and compositions for preparing and analyzing DNA molecules to identify at least one somatic mutation associated with cancer. Cell-free DNA is extracted from at least one plasma fraction of a blood sample of a subject, and optionally extracting cellular DNA from a fraction of the blood sample containing a plurality of leukocytes. Targeted multiplex amplification is performed on the extracted cell-free DNA or DNA derived therefrom to amplify 50-1,000 target loci each encompassing at least one somatic mutation associated with the cancer, and optionally on the extracted cellular DNA or DNA derived therefrom to amplify 10 or more of the 50-1,000 target loci. The amplified DNA is analyzed by sequencing to identify the at least one somatic mutation that is present in the plasma-derived amplified DNA and that is not a clonal hematopoiesis (CH) mutation present in the leukocyte-derived amplified DNA.

The present disclosure provides methods and compositions for preparing and analyzing DNA molecules to identify at least one somatic mutation associated with cancer. Cell-free DNA is extracted from at least one plasma fraction of a blood sample of a subject, and optionally extracting cellular DNA from a fraction of the blood sample containing a plurality of leukocytes. Targeted multiplex amplification is performed on the extracted cell-free DNA or DNA derived therefrom to amplify 50-1,000 target loci each encompassing at least one somatic mutation associated with the cancer, and optionally on the extracted cellular DNA or DNA derived therefrom to amplify 10 or more of the 50-1,000 target loci. The amplified DNA is analyzed by sequencing to identify the at least one somatic mutation that is present in the plasma-derived amplified DNA and that is not a clonal hematopoiesis (CH) mutation present in the leukocyte-derived amplified DNA.

This document provides methods and materials for assessing and / or treating subjects (e.g., humans) suspected of having cancer. For example, this document provides methods and materials for a nucleic acid sequence analysis which can determine a sequence of T cell receptor. In some cases, determining a sequence of T cell receptor (and, optionally, identifying the presence of one or more mutations and / or identifying the presence of aneuploidy) in DNA (e.g., cellular DNA and cell-free DNA (cfDNA)) in a fluid sample (e.g., a cerebrospinal fluid sample) obtained from a subject (e.g., a human subject such as a human suspected of having cancer) can be used to identify the subject as having cancer.

The invention discloses an application of brucein A in preparation of a DNA damage reaction inhibitor drug, and relates to the technical field of biological medicines. The inhibitor drug is based on brucein A and simultaneously inhibits homologous recombination repair and non-homologous end ligation in cells. In drug screening, it is found for the first time that the brucein A can effectively inhibit DNA damage response of cells and can inhibit two main DNA damage repair approaches, namely homologous recombination repair and non-homologous end connection; in addition, the bruceine A is combined with a chemotherapeutic drug for use, so that the sensitivity of the triple negative breast cancer cell MDA-MB-231 to the chemotherapeutic drug cis-platinum can be remarkably enhanced.